

Remarks

Restriction has been required among five claim groups.

Group IV is characterized in the office action as drawn to a method of inhibiting Vif multimerization “comprising PXP”. It is assumed that what is meant is a method comprising administering *a peptide comprising the PXP motif*. Claim 2 contains the language “peptide comprising the PXP motif”. Subject to this interpretation of Group IV, applicants hereby elect that group, containing claims 1, 2, 7-15, 17, 19 and 20.

Election of a species has been required. Applicants hereby elect the species of SEQ ID NO:11.

The claims readable on the elected species include claims 1, 2, 5, 7, 8, 9, 12, 13, 14, 15, 17, 19 and 20.

Respectfully submitted,  
HUI ZHANG, *et al.*



DANIEL A. MONACO  
Registration No. 30,480  
DRINKER BIDDLE & REATH LLP.  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
(215) 988-3312 - phone  
(215) 988-2757 – Fax  
*Attorney for the Applicants*